Replies to post #42607 on CV Sciences Inc (CVSI)

[super_trades]

Yes he is trashing CVSI now

[SpaceLady]

Definitely touting Elixinol, and a bit negative on CVSI and the other stock mentioned. But when comparing to CVSI, I read that he is heavily comparing management and PR. I bet he will change his tune once uplist occurs, and CVSI has more latitude to advertise.
Ehh. I still prefer CVSI, although for grins and giggles, I should buy a lot or two of this stock.

[jefra1965]

Both Elixinol and CV Sciences Inc. (CVSI:OTCQB) have strong controls and solid relationships over their supply chain. Elixinol, led by founder Paul Benhaim, has carefully sourced hemp for over 20 years, with key relationships and quality farmers. Elixinol products are mostly organically grown, while CV Sciences (OTCBB:CVSI) buys its hemp supply as a non-organic commodity.

CVSI is No. 1 in proven quality, proven safety and consistency. CVSI has done a toxicology report and GRAS to prove it.

Like CWEB, CV Sciences' majority revenue source is independent retailers. Since we believe the initial stocking rush has completed, we suspect CVSI declining growth rate continues. Investor's with high quarterly expectations should be cautious.

Speculative at best. We heard from TOMC the retail stores are growing.

We have several growing concerns:

Retailers we have spoken with have complained about CVSI sales department having challenges. It took weeks, and several requests, just to get brochures or product sent.

How many stores?? If any... Speculative at best. We heard from TOMC the retail stores are growing.

CV management continues to insist on promoting its bizarre "pet project"—a CBD-laced smoking cessation drug. That would be fine, only without a patent, which hasn't been forthcoming, the idea is essentially worthless. Management gave away a tremendous amount of shares, for the drug, so perhaps feel obligated to justify the gift.

CVSI management stubbornly continues to split the company into two parts, confusing investors, none of whom (that we know) has any interest beyond CBD sales, especially with no patent. Yet, CVSI still devotes nearly half its precious presentation time and space to it.

The SPEND in R&D has been minimum. This is all non-consequential. Of no value @ the moment and NOT costing much. Written on purpose to tout the other company.
I have compared the financials a long time ago and I believe CVSI's financial performance is a lot better. He also forgot to mention that CVSI dominates the US market. And I have no idea how Elixinol will fare after the FDA announcement next month.

CVSI Q3

Mr. Dowling added, “Our drug development program is making steady progress in advancing our proprietary lead drug candidate - CVSI-007 - which addresses the multibillion dollar smokeless tobacco use and addiction market. We continue to make progress with our pre-clinical program, anticipating filing an Investigational New Drug application in 2019. We are confident that our continued growth and profitability will allow us to initially pursue our drug development plans without the need for additional outside capital in the near term. Given the industry’s robust growth momentum, we believe we have the right strategies in place and remain committed to achieve a strong 2018 finish.

Article

In addition, management has pretty much decided to ignore its large base of retail shareholders, those responsible for building up share price in the first place. We dislike companies who treat people and shareholders with contempt. Many new "rookie" CEO's make mistakes—when their shares go up 10X, the head swells. Trouble usually follows.

His personal opinion. I personally don't feel that way.

https://c.stockcharts.com/c-sc/sc?s=CVSI&p=D&b=5&g=0&i=t8478773840c&r=1549038316902
CVSI shares have been consolidating; volume declining.
In summary, our investigation found Elixinol to be more open, aggressive, with a far better balanced team, and a strong commitment to enhancing shareholder value.

We do agree CVSI is most likely to become first to "uplist" to a senior U.S. exchange (having already applied to NASDAQ) and expectations of a subsequent bounce appear valid. We continue to hold shares in anticipation.

Down back to earth.

We further argue there are strong odds all of these larger CBD companies doing well in 2019—we believe there will be numerous announcements—and growing excitement, as deals with mainstream partners, and retailers such as Whole Foods, pop. Other, mostly Canadian cannabis competitors, rushing into the bonanza, will take at least two years to develop any serious supply.

He completely forgot about the FDA and who is better positioned to take off in 2019.

CVSI is a better play by far. JMHO.

LONG CVSI.

[chilling]

his disclaimer shows he owns and buys elixinol, hes pimping it. weak.
CVSI will be first to uplist

[Chirodoctor]

And the author admits they have ties to elixinol And receive a modest fee for consulting. Clearly biased